Company / Current Assets
Avalo Therapeutics, Inc. Current Assets History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$105.3M
FY2025
5-year range
$8.4M / $138.9M
FY2021-FY2025
Trend
-24.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Assets has fluctuated over the past 9 years, ranging from $8M in FY2023 to $139M in FY2024.
Based on SEC 10-K filings.
$105M in FY2025 with a 5-year CAGR of +32.3%.
Improved from $8M to $105M over the past 2 years.
Current Assets over time
Growth rates
- 3-Year CAGR
- +85.8%
- 5-Year CAGR
- +32.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +32.3%, indicating consistent growth.
- In FY2025, current assets decreased 24.2% year-over-year.
- Peak current assets was recorded in FY2024.
- Lowest current assets in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $105.3M | -24.2% |
| FY2024 | $138.9M | +1554.4% |
| FY2023 | $8.4M | -48.9% |
| FY2022 | $16.4M | -73.5% |
| FY2021 | $61.8M | +137.8% |
| FY2020 | $26.0M | +46.7% |
| FY2019 | $17.7M | -19.2% |
| FY2018 | $21.9M | +105.5% |
| FY2017 | $10.7M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026